Proto-oncogene c-Rel
Details
- Name
- Proto-oncogene c-Rel
- Kind
- protein
- Synonyms
- Not Available
- Gene Name
- REL
- UniProtKB Entry
- Q04864Swiss-Prot
- Organism
- Humans
- NCBI Taxonomy ID
- 9606
- Amino acid sequence
>lcl|BSEQ0053848|Proto-oncogene c-Rel MASGAYNPYIEIIEQPRQRGMRFRYKCEGRSAGSIPGEHSTDNNRTYPSIQIMNYYGKGK VRITLVTKNDPYKPHPHDLVGKDCRDGYYEAEFGQERRPLFFQNLGIRCVKKKEVKEAII TRIKAGINPFNVPEKQLNDIEDCDLNVVRLCFQVFLPDEHGNLTTALPPVVSNPIYDNRA PNTAELRICRVNKNCGSVRGGDEIFLLCDKVQKDDIEVRFVLNDWEAKGIFSQADVHRQV AIVFKTPPYCKAITEPVTVKMQLRRPSDQEVSESMDFRYLPDEKDTYGNKAKKQKTTLLF QKLCQDHVETGFRHVDQDGLELLTSGDPPTLASQSAGITVNFPERPRPGLLGSIGEGRYF KKEPNLFSHDAVVREMPTGVSSQAESYYPSPGPISSGLSHHASMAPLPSSSWSSVAHPTP RSGNTNPLSSFSTRTLPSNSQGIPPFLRIPVGNDLNASNACIYNNADDIVGMEASSMPSA DLYGISDPNMLSNCSVNMMTTSSDSMGETDNPRLLSMNLENPSCNSVLDPRDLRQLHQMS SSSMSAGANSNTTVFVSQSDAFEGSDFSCADNSMINESGPSNSTNPNSHGFVQDSQYSGI GSMQNEQLSDSFPYEFFQV
- Number of residues
- 619
- Molecular Weight
- 68519.05
- Theoretical pI
- Not Available
- GO Classification
- Processescanonical NF-kappaB signal transduction / non-canonical NF-kappaB signal transduction / positive regulation of canonical NF-kappaB signal transductionComponentscytoplasm
- General Function
- Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator
- Specific Function
- Dna-binding transcription activator activity, rna polymerase ii-specific
- Pfam Domain Function
- Signal Regions
- Not Available
- Transmembrane Regions
- Not Available
- Cellular Location
- Nucleus
- Gene sequence
>lcl|BSEQ0053849|Proto-oncogene c-Rel (REL) ATGGCCTCCGGTGCGTATAACCCGTATATAGAGATAATTGAACAACCCAGGCAGAGGGGA ATGCGTTTTAGATACAAATGTGAAGGGCGATCAGCAGGCAGCATTCCAGGGGAGCACAGC ACAGACAACAACCGAACATACCCTTCTATCCAGATTATGAACTATTATGGAAAAGGAAAA GTGAGAATTACATTAGTAACAAAGAATGACCCATATAAACCTCATCCTCATGATTTAGTT GGAAAAGACTGCAGAGACGGCTACTATGAAGCAGAATTTGGACAAGAACGCAGACCTTTG TTTTTCCAAAATTTGGGTATTCGATGTGTGAAGAAAAAAGAAGTAAAAGAAGCTATTATT ACAAGAATAAAGGCAGGAATCAATCCATTCAATGTCCCTGAAAAACAGCTGAATGATATT GAAGATTGTGACCTCAATGTGGTGAGACTGTGTTTTCAAGTTTTTCTCCCTGATGAACAT GGTAATTTGACGACTGCTCTTCCTCCTGTTGTCTCGAACCCAATTTATGACAACCGTGCT CCAAATACTGCAGAATTAAGGATTTGTCGTGTAAACAAGAATTGTGGAAGTGTCAGAGGA GGAGATGAAATATTTCTACTTTGTGACAAAGTTCAGAAAGATGACATAGAAGTTCGTTTT GTGTTGAACGATTGGGAAGCAAAAGGCATCTTTTCACAAGCTGATGTACACCGTCAAGTA GCCATTGTTTTCAAAACTCCACCATATTGCAAAGCTATCACAGAACCCGTAACAGTAAAA ATGCAGTTGCGGAGACCTTCTGACCAGGAAGTTAGTGAATCTATGGATTTTAGATATCTG CCAGATGAAAAAGATACTTACGGCAATAAAGCAAAGAAACAAAAGACAACTCTGCTTTTC CAGAAACTGTGCCAGGATCACGTAGAAACAGGGTTTCGCCATGTTGACCAGGATGGTCTT GAACTCCTGACATCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGTT AATTTTCCTGAGAGACCAAGACCTGGTCTCCTCGGTTCAATTGGAGAAGGAAGATACTTC AAAAAAGAACCAAACTTGTTTTCTCATGATGCAGTTGTGAGAGAAATGCCTACAGGGGTT TCAAGTCAAGCAGAATCCTACTATCCCTCACCTGGGCCCATCTCAAGTGGATTGTCACAT CATGCCTCAATGGCACCTCTGCCTTCTTCAAGCTGGTCATCAGTGGCCCACCCCACCCCA CGCTCAGGCAATACAAACCCACTGAGTAGTTTTTCAACAAGGACACTTCCTTCTAATTCG CAAGGTATCCCACCATTCCTGAGAATACCTGTTGGGAATGATTTAAATGCTTCTAATGCT TGCATTTACAACAATGCCGATGACATAGTCGGAATGGAAGCGTCATCCATGCCATCAGCA GATTTATATGGTATTTCTGATCCCAACATGCTGTCTAATTGTTCTGTGAATATGATGACA ACCAGCAGTGACAGCATGGGAGAGACTGATAATCCAAGACTTCTGAGCATGAATCTTGAA AACCCCTCATGTAATTCAGTGTTAGACCCAAGAGACTTGAGACAGCTCCATCAGATGTCC TCTTCCAGTATGTCAGCAGGCGCCAATTCCAATACTACTGTTTTTGTTTCACAATCAGAT GCATTTGAGGGATCTGACTTCAGTTGTGCAGATAACAGCATGATAAATGAGTCGGGACCA TCAAACAGTACTAATCCAAACAGTCATGGTTTTGTTCAAGATAGTCAGTATTCAGGTATT GGCAGTATGCAAAATGAGCAATTGAGTGACTCCTTTCCATATGAATTTTTTCAAGTATAA
- Chromosome Location
- 2
- Locus
- 2p16.1
- External Identifiers
Resource Link UniProtKB ID Q04864 UniProtKB Entry Name REL_HUMAN GeneCard ID REL HGNC ID HGNC:9954 KEGG ID hsa:5966 NCBI Gene ID 5966 - General References
- Not Available
Associated Data
- Drug Relations
Drug Drug group Pharmacological action? Type Actions Details (4R,5R)-1,2-dithiane-4,5-diol experimental yes target inhibitor Details Go-6976 investigational yes target inhibitor Details Rocaglamide experimental yes target inhibitor Details Tyloxapol approved, investigational yes target inhibitor Details Tepilamide fumarate investigational yes target inhibitor Details Recoflavone investigational yes target modulator Details Vadimezan investigational yes target modulator Details Edasalonexent investigational yes target inhibitor Details Triptolide investigational yes target inhibitor Details Laquinimod investigational yes target modulator Details Sulfasalazine approved yes target activator Details Parthenolide approved, investigational yes target inhibitor Details